Edition:
United Kingdom

TRACON Pharmaceuticals Inc (TCON.OQ)

TCON.OQ on NASDAQ Stock Exchange Global Market

1.80USD
12 Oct 2018
Change (% chg)

-- (--)
Prev Close
$1.80
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
17,283
52-wk High
$3.55
52-wk Low
$1.62

Chart for

About

TRACON Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics for cancer, wet age-related macular degeneration (wet AMD) and fibrotic diseases. The Company's research focuses on antibodies that bind to the endoglin receptor, which is... (more)

Overall

Beta: --
Market Cap(Mil.): $61.63
Shares Outstanding(Mil.): 16.66
Dividend: --
Yield (%): --

Financials

  TCON.OQ Industry Sector
P/E (TTM): -- 85.91 32.75
EPS (TTM): -1.76 -- --
ROI: -107.08 1.70 14.60
ROE: -146.37 3.17 16.33

BRIEF-Tracon Pharmaceuticals Files For Offering Of Up To 27.4 Mln Shares Of Common Stock By The Selling Stockholders

* TRACON PHARMACEUTICALS INC FILES FOR OFFERING OF UP TO 27.4 MILLION SHARES OF COMMON STOCK BY THE SELLING STOCKHOLDERS Source text: [https://bit.ly/2KQef7f] Further company coverage:

10 May 2018

BRIEF-TRACON Pharmaceuticals Reports Qtrly Loss Per Share $0.46

* TRACON PHARMACEUTICALS REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

09 May 2018

BRIEF-Tracon Pharmaceuticals Says Patricia Bitar Notified That Resigning As Co's CFO

* TRACON PHARMACEUTICALS INC - ON APRIL 30, PATRICIA L. BITAR NOTIFIED THAT RESIGNING AS CO'S CFO, EFFECTIVE JUNE 15, 2018- SEC FILING Source text for Eikon: (https://bit.ly/2w9w9yD) Further company coverage:

04 May 2018

Earnings vs. Estimates